Not intended for use by individuals under 18 years of age
For people taking between 0.5 mg and 2.4 mg of subcutaneous semaglutide, nausea increased from 23% of those taking 0.5 mg to 68% of those taking 2.4 mg, and vomiting increased from 9% to 45%
With rising insulin levels and blood sugar levels, our bodies will begin to store excess sugar as fat, says Midis Chief Medical Officer, Kathleen Jordan, MD
Drucker Lunenfeld-Tanenbaum Research Institute, Sinai Health, and University of Toronto 2025 Breakthrough Prize in Life Sciences For the discovery and characterization of GLP-1 and revealing its physiology and potential in treating diabetes and obesity.
The Results: Breaking Down 28.7% Weight Loss Primary Efficacy Outcomes Both retatrutide doses met all primary and key secondary endpoints with statistical and clinical significance: The 12mg dose achieved the highest weight loss on record for a Phase 3 obesity trial, with more than 1 in 4 pounds lost from baseline body weight
Film yourself doing it